Risk factors for linezolid-associated thrombocytopenia and negative effect of carbapenem combination

Kilic, Esra; Bulut, Cemal; SÖNMEZER, MELİHA; Ozel, Ozlem; Hatipoglu, Cigdem; Ertem, Gunay; Tulek, Necla; Kinikli, Sami

doi:10.3855/jidc.10859

Risk factors for linezolid-associated thrombocytopenia and negative effect of carbapenem combination

Kilic E. K., Bulut C., SÖNMEZER M. Ç., Ozel O., Hatipoglu C. A., Ertem G. T., ...Daha Fazla

JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, cilt.13, sa.10, ss.886-891, 2019 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 13 Sayı: 10
Basım Tarihi: 2019
Doi Numarası: 10.3855/jidc.10859
Dergi Adı: JOURNAL OF INFECTION IN DEVELOPING COUNTRIES
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.886-891
Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
Hacettepe Üniversitesi Adresli: Evet

Özet

Introduction: Linezolid is a synthetic antimicrobial agent with a broad spectrum of activity against virtually all Gram-positive bacteria. Although linezolid is generally well tolerated, the prolonged use of linezolid can lead to myelosuppression, including neutropenia, thrombocytopenia, and anemia. The aim of this study was investigating the risk factors for thrombocytopenia in patients who received linezolid therapy.